Sienna Biopharmaceuticals, Inc. (SNNAQ)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -61.69 Million | -41.08 Million |
| Net Income | - | - | - | - | -73.47 Million | -50.54 Million |
| Depreciation & Amortization | - | - | - | - | 157 Thousand | 120 Thousand |
| Deferred income taxes | - | - | - | - | 3000.00 | 5000.00 |
| Stock-based compensation | - | - | - | - | 4.7 Million | 2.11 Million |
| Change in working capital | - | - | - | - | 3.16 Million | 1.44 Million |
| Other non-cash items | - | - | - | - | 3.75 Million | 5.77 Million |
| Investing Cash Flow | - | - | - | - | -39 Thousand | -266 Thousand |
| Investments in PPE | - | - | - | - | -39 Thousand | -274 Thousand |
| Acquisitions | - | - | - | - | - | 8000.00 |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | 8000.00 |
| Financing Cash Flow | - | - | - | - | 35.96 Million | 106.77 Million |
| Debt repayment | - | - | - | - | -29.86 Million | -3.9 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | 6.09 Million | 66.56 Million |
| Other Financing Activities | - | - | - | - | 29.86 Million | 40.21 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | 2.16 Million | 2.87 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | 997 Thousand | 1.44 Million |
| Cash at beginning of period | - | - | - | 48.52 Million | 74.64 Million | 9.09 Million |
| Cash at end of period | - | - | - | 48.52 Million | 48.7 Million | 74.46 Million |
| Capital Expenditure | - | - | - | - | -39 Thousand | -274 Thousand |
| Effect of forex changes on cash | - | - | - | - | -169 Thousand | -52 Thousand |
| Net cash flow / Change in cash | - | - | - | - | -25.94 Million | 65.37 Million |
| Free Cash Flow | - | - | - | - | -61.73 Million | -41.35 Million |
| Breakdown | 2022 FY | 2021 FY | 2020 FY | 2019 FY | 2019 Q3 | 2019 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | -3.97 Million | -8.26 Million |
| Depreciation & Amortization | - | - | - | - | 36 Thousand | 37 Thousand |
| Deferred income taxes | - | - | - | - | 26.42 Million | 1000.00 |
| Stock-based compensation | - | - | - | - | 1.4 Million | 871 Thousand |
| Change in working capital | - | - | - | - | -8.27 Million | -1.21 Million |
| Other non-cash items | - | - | - | - | -33.46 Million | 151 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | -20 Million | 452 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 452 Thousand |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | - | 48.52 Million | 49.38 Million | 57.35 Million |
| Cash at end of period | - | - | - | 48.52 Million | 11.54 Million | 49.38 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | 1000.00 | 3000.00 |
| Net cash flow / Change in cash | - | - | - | - | -37.84 Million | -7.96 Million |
| Free Cash Flow | - | - | - | - | -17.84 Million | -8.41 Million |
8987
9017
ALLT
0QOJ
TKYVY
0113